<DOC>
	<DOCNO>NCT00000642</DOCNO>
	<brief_summary>Part 1 : To determine safety , tolerance , pharmacokinetic profile ( blood level ) recombinant CD4 immunoglobulin G ( rCD4-IgG ) intravenous bolus administration ( give vein ) woman HIV infection third trimester ( last three month pregnancy ) . To determine safety maternal/fetal transfer rCD4-IgG infant born mother enter study . To obtain preliminary indication antiviral immunologic effect rCD4-IgG HIV seropositive pregnant woman newborn . AMENDED : Part 2 : To determine safety profile rCD4-IgG HIV-1-infected woman onset labor newborn . To determine extent placental transfer rCD4-IgG administer mother onset labor . To determine pharmacokinetics rCD4-IgG newborn . To obtain preliminary evidence ability rCD4-IgG prevent intrapartum transmission HIV-1 mother fetus . An agent prevent HIV infection desirable risk infection well pregnant female newborn population . Such agent may help prevent progression disease infant child early stage infection . In theory , rCD4-IgG antiviral effect .</brief_summary>
	<brief_title>A Phase I Study Safety Pharmacokinetics Recombinant CD4 Immunoglobulin G ( rCD4-IgG ) HIV-1 Seropositive Women During Last Trimester Pregnancy Their Newborns</brief_title>
	<detailed_description>An agent prevent HIV infection desirable risk infection well pregnant female newborn population . Such agent may help prevent progression disease infant child early stage infection . In theory , rCD4-IgG antiviral effect . Part 1 : Per original protocol , total six pregnant woman enrol Groups A B . Patients Group A receive rCD4-IgG onset labor , Group B receive rCD4-IgG twice per week , begin 1 week expect date delivery . Newborns treat Part 1 study . AMENDED : In Part 2 study , total nine pregnant woman enrol Groups C , D , E receive high dose rCD4-IgG onset labor . If mother deliver 18 hour rCD4-IgG injection , second injection dose administer ; daily injection give thereafter delivery . The newborn receive 1 3 dos rCD4-IgG daily first 5 day life . Infants enrol sequentially dose level .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>CD4 Immunoadhesins</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Iron , multivitamin , short course treatment correctable medical problem ( e.g. , urinary tract infection ) , oral trimethoprim/sulfamethoxazole ( TMP/SMX ) aerosolize pentamidine prophylaxis Pneumocystis carinii pneumonia ( PCP ) , prophylactic antifungal therapy , isoniazid ( INH ) therapy . Acetaminophen . Other supportive therapy ( blood blood product , vaginal cream , antiemetic , antidiarrheal , cough medicine ) . Specific agent used delivery , oxytocic agent anesthetic . Participation protocol prevent newborn receive medication . Concurrent Treatment : Allowed : Blood blood product transfusion . Gamma globulin prophylaxis infection varicella virus hepatitis virus , RhoGAM case maternalfetal incompatibility . Risk Behavior : Allowed : Illicit drug use . Patients must : In third trimester pregnancy , join study newborn child . Willing able sign inform consent . Available followup least 3 month . The child available followup least 1 year delivery , preferably longer . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Medical complication include , limited , insulin dependent diabetes mellitus ( IDDM ) , hypertensive disorder severe preeclampsia , eclampsia , chronic hypertension , cardiovascular disease include rheumatic congenital heart disease , collagen vascular disease , endocarditis , renal disease . Hematological condition include , limited , hemoglobinopathy , coagulopathy , idiopathic thrombocytopenic purpura ( ITP ) , maternalfetal blood incompatibility isoimmunization ( e.g. , Rhnegative mother positive indirect Coomb 's test time pregnancy ) . Neurological disease ( ) include seizure disorder . Bronchopulmonary disease , severe asthma . Evidence fetal intolerance intrauterine environment . Concurrent Medication : Excluded : Antiretroviral agent : Suramin , ribavirin , HPA23 , phosphonoformate , ansamycin , zidovudine ( AZT ) , didanosine ( ddI ) , dideoxycytidine ( ddC ) . Other antiviral drug , include acyclovir ganciclovir . Immunomodulating agent : Interleukin 2 , interferon , thymic hormone , agent . Cytolytic chemotherapeutic agent . Corticosteroids . Immunoglobulin preparation . Concurrent Treatment : Excluded : Radiation therapy . Regular administration gamma globulin . Patients follow exclude : Serious medical surgical complication pregnancy and/or delivery require treatment delivery might compromise health mother fetus . Any HIVrelated complication require antiretroviral therapy pregnancy , include encephalopathy opportunistic infection . Systemic infection require IV therapy month prior enrollment study ( IV treatment pyelonephritis permit ) . Prior Medication : Excluded : Recombinant CD4 immunoglobulin G ( rCD4IgG ) . Excluded within 4 week study entry : Antiretroviral agent : Suramin , ribavirin , HPA23 , phosphonoformate , ansamycin , zidovudine ( AZT ) , didanosine ( ddI ) , dideoxycytidine ( ddC ) . Other antiviral drug , include acyclovir ganciclovir . Immunomodulating agent : Interleukin 2 , interferon , thymic hormone , agent . Cytolytic chemotherapeutic agent . Corticosteroids . Immunoglobulin preparation . Prior Treatment : Excluded within 4 week study entry : Radiation therapy . History poor medical compliance ( discretion investigator ) . Current illicit drug use .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Pregnancy Trimester , Third</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>IgG</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Antigens , CD4</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Immunization , Passive</keyword>
</DOC>